Tourmaline Bio announced that the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program for TOUR006, a long-acting, fully human, anti-IL-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease and other cardiovascular diseases. TRANQUILITY is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity C-reactive protein at baseline, and chronic kidney disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Tourmaline Bio reports Q1 EPS (55c), consensus (67c)
- 3 Best Stocks to Buy Now, 3/26/2024, According to Top Analysts
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio price target raised to $74 from $43 at Truist